Philip D Harvey1,2,3, Cynthia O Siu1,2,3, Antony D Loebel1,2,3. 1. Dr. Harvey is with the University of Miami Miller School of Medicine in Miami, Florida, and the Research Service of the Bruce W. Carter VA Medical Center in Miami, Florida. 2. Dr. Siu is with COS and Associates Ltd. in Central District, Hong Kong. 3. Dr. Loebel is with Sunovion Pharmaceuticals Inc., in Fort Lee, New Jersey.
Abstract
Objective: The objective of this post-hoc analysis was to evaluate the effect of lurasidone and quetiapine extended-release (XR) on insight and judgment and assess the longitudinal relationships between improvement in insight and cognitive performance, functional capacity, quality of well-being, and depressive symptoms in patients with schizophrenia. Design: Clinically unstable patients with schizophrenia (N=488) were randomized to once-daily, fixed-dose treatment with lurasidone 80mg, lurasidone 160mg, quetiapine XR 600mg, or placebo, followed by a long-term, double-blind, flexible-dose continuation study involving these agents. Results: Significantly greater improvement in insight and judgment (assessed by the Positive and Negative Syndrome Scale G12 item) for the lurasidone and quetiapine XR groups, compared to the placebo group, was observed at Week 6. Over a subsequent six-month continuation period, the flexible dose lurasidone group showed significantly greater improvement in insight from acute phase baseline compared to the flexible-dose quetiapine XR group (QXR-QXR) (p=0.032). Improvement in insight was significantly correlated with improvement in cognition (p=0.014), functional capacity (p=0.006, UPSA-B), quality of well-being (p=0.033, QWB), and depressive symptoms (p=0.05, Montgomery-Åsberg Depression Rating Scale [MADRS] score) across treatment groups and study periods. Conclusion: In this post-hoc analysis, flexibly dosed lurasidone 40 to 160mg/d was found to be associated with significantly greater improvement in insight compared to flexibly dosed quetiapine XR 200 to 800mg/d over long-term treatment in patients with schizophrenia. Across treatment groups, improvement in insight and judgment was significantly associated with improvement in cognition, functional capacity, quality of well-being, and depressive symptoms over time.
RCT Entities:
Objective: The objective of this post-hoc analysis was to evaluate the effect of lurasidone and quetiapine extended-release (XR) on insight and judgment and assess the longitudinal relationships between improvement in insight and cognitive performance, functional capacity, quality of well-being, and depressive symptoms in patients with schizophrenia. Design: Clinically unstable patients with schizophrenia (N=488) were randomized to once-daily, fixed-dose treatment with lurasidone 80mg, lurasidone 160mg, quetiapine XR 600mg, or placebo, followed by a long-term, double-blind, flexible-dose continuation study involving these agents. Results: Significantly greater improvement in insight and judgment (assessed by the Positive and Negative Syndrome Scale G12 item) for the lurasidone and quetiapine XR groups, compared to the placebo group, was observed at Week 6. Over a subsequent six-month continuation period, the flexible dose lurasidone group showed significantly greater improvement in insight from acute phase baseline compared to the flexible-dose quetiapine XR group (QXR-QXR) (p=0.032). Improvement in insight was significantly correlated with improvement in cognition (p=0.014), functional capacity (p=0.006, UPSA-B), quality of well-being (p=0.033, QWB), and depressive symptoms (p=0.05, Montgomery-Åsberg Depression Rating Scale [MADRS] score) across treatment groups and study periods. Conclusion: In this post-hoc analysis, flexibly dosed lurasidone 40 to 160mg/d was found to be associated with significantly greater improvement in insight compared to flexibly dosed quetiapine XR 200 to 800mg/d over long-term treatment in patients with schizophrenia. Across treatment groups, improvement in insight and judgment was significantly associated with improvement in cognition, functional capacity, quality of well-being, and depressive symptoms over time.
Authors: Antony Loebel; Josephine Cucchiaro; Jane Xu; Kaushik Sarma; Andrei Pikalov; John M Kane Journal: Schizophr Res Date: 2013-04-11 Impact factor: 4.939
Authors: Antony Loebel; Josephine Cucchiaro; Kaushik Sarma; Lei Xu; Chuanchieh Hsu; Amir H Kalali; Andrei Pikalov; Steven G Potkin Journal: Schizophr Res Date: 2013-02-13 Impact factor: 4.939
Authors: Dante Durand; Martin Strassnig; Samir Sabbag; Felicia Gould; Elizabeth W Twamley; Thomas L Patterson; Philip D Harvey Journal: Eur Neuropsychopharmacol Date: 2014-07-25 Impact factor: 4.600
Authors: Błażej Misiak; Dorota Frydecka; Jan A Beszłej; Ahmed A Moustafa; Piotr Tybura; Jolanta Kucharska-Mazur; Agnieszka Samochowiec; Przemysław Bieńkowski; Jerzy Samochowiec Journal: Int Clin Psychopharmacol Date: 2016-07 Impact factor: 1.659
Authors: William Sellwood; Anthony P Morrison; Rosie Beck; Suzanne Heffernan; Heather Law; Richard P Bentall Journal: PLoS One Date: 2013-12-20 Impact factor: 3.240
Authors: Cynthia O Siu; Philip D Harvey; Ofer Agid; Mary Waye; Carla Brambilla; Wing-Kit Choi; Gary Remington Journal: Schizophr Res Cogn Date: 2015-06-09